The contributions of HIF-target genes to tumor growth in RCC

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhang, Ting ^a   Niu, Xiaohua ^b   Liao, Lili ^b,c   Cho, Eun Ah ^c   Yang, Haifeng ^b,c  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN IGFIR; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGPTL4 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CCND1 GENE; CONTROLLED STUDY; EGLN3 GENE; ENO2 GENE; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GLUT1 GENE; HUMAN; HUMAN CELL; IGFBP3 GENE; IMMUNOCOMPROMISED PATIENT; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VEGF GENE;

ANGIOPOIETINS; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLIN D1; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE; PHOSPHOPYRUVATE HYDRATASE; RECEPTOR, IGF TYPE 1; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896705001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080544     Document Type: Article

References (46)

1. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M et al. (2004) Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10: 6282S-6289S. doi:10.1158/1078-0432.CCR-050013. PubMed: 15448018.
2. Kaelin WG Jr. (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682. doi:10.1038/nrc885. PubMed: 12209156.
3. Ivan M, Kondo K, Yang H, Kim W, Valiando J et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468. doi:10.1126/science.1059817. PubMed: 11292862.
4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472. doi:10.1126/science. 1059796. PubMed: 11292861.
5. Yu F, White SB, Zhao Q, Lee FS (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 98: 9630-9635. doi:10.1073/pnas.181341498. PubMed: 11504942.
6. Rini BI, Sosman JA, Motzer RJ (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96: 286-290. doi:10.1111/j.1464-410X. 2005.05616.x. PubMed: 16042715.
7. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998. doi:10.1158/1078-0432.CCR-07- 0078. PubMed: 17606733.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124. doi:10.1056/NEJMoa065044. PubMed: 17215529.
9. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000. doi:10.1016/S1470-2045(09)70240-2. PubMed: 19796751.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134. doi:10.1056/NEJMoa060655. PubMed: 17215530.
11. Sonpavde G, Hutson TE, Rini BI (2008) Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 17: 741-748. doi:10.1517/13543784.17.5.741. PubMed: 18447599.
12. Bukowski RM (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 10: 635-645. doi:10.1586/era.10.38. PubMed: 20469994.
13. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246. doi:10.1016/S1535-6108(02)00043-0. PubMed: 12086860.
14. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM et al. (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255. doi:10.1016/S1535-6108(02)00044-2. PubMed: 12086861.
15. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLOS Biol 1: E83. PubMed: 14691554.
16. Yan Q, Bartz S, Mao M, Li L, Kaelin WG Jr. (2007) The hypoxiainducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol 27: 2092-2102. doi:10.1128/MCB.01514-06. PubMed: 17220275.
17. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA et al. (2007) Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 27: 5381-5392. doi:10.1128/MCB.00282-07. PubMed: 17526729.
18. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E et al. (2008) Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7: 1619-1627. doi:10.4161/cbt.7.10.6583. PubMed: 19018165.
19. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM et al. (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570. doi:10.1101/gad.1399906. PubMed: 16510872.
20. Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K et al. (2003) Hypoxia inducible factor activates the transforming growth factor-alpha/ epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278: 44966-44974. doi:10.1074/jbc.M305502200. PubMed: 12944410.
21. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C et al. (2009) Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28: 2513-2523. doi: 10.1038/onc.2009.116. PubMed: 19448672.
22. Wright TM, Rathmell WK (2010) Identification of Ror2 as a hypoxiainducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J Biol Chem 285: 12916-12924. doi:10.1074/jbc.M109.073924. PubMed: 20185829.
23. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O (2004) Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2: 89-95. PubMed: 14985465.
24. Tan MJ, Teo Z, Sng MK, Zhu P, Tan NS (2012) Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res 10: 677-688. doi:10.1158/1541-7786.MCR-11-0519. PubMed: 22661548.
25. Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021. doi:10.1038/35082500. PubMed: 11429595.
26. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686. doi:10.1128/MCB.25.13.5675-5686.2005. PubMed: 15964822.
27. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G et al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488: 337-342. doi:10.1038/nature11331. PubMed: 22895339.
28. Kaelin WG Jr. (2011) Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol 76: 335-345. doi:10.1101/sqb.2011.76.010975. PubMed: 22089927.
29. Schlisio S (2009) Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. J Cell Mol Med 13: 4104-4112. doi:10.1111/j.1582-4934.2009.00881.x. PubMed: 19691672.
30. Xie L, Xiao K, Whalen EJ, Forrester MT, Freeman RS et al. (2009) Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal 2: ra33. PubMed: 19584355.
31. Su Y, Loos M, Giese N, Hines OJ, Diebold I et al. (2010) PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer 103: 1571-1579. doi:10.1038/sj.bjc.6605936. PubMed: 20978507.
32. Adekola K, Rosen ST, Shanmugam M (2012) Glucose transporters in cancer metabolism. Curr Opin Oncol 24: 650-654. doi:10.1097/CCO. 0b013e328356da72. PubMed: 22913968.
33. Jogie-Brahim S, Feldman D, Oh Y (2009) Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 30: 417-437. doi:10.1210/er.2008-0028. PubMed: 19477944.
34. Huang D, Ding Y, Zhou M, Rini BI, Petillo D et al. (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071. doi: 10.1158/0008-5472.CAN-09-3965. PubMed: 20103651.
35. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S et al. (2010) Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 9: 2793-2802. doi:10.1158/1535-7163.MCT- 10-0477. PubMed: 20699227.
36. Pestell RG (2013) New roles of cyclin d1. Am J Pathol 183: 3-9. doi:10.1016/S0002-9440(13)00360-X. PubMed: 23790801.
37. Taniguchi CM, Finger EC, Krieg AJ, Wu C, Diep AN et al. (2013) Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med, 19: 1325-30. PubMed: 24037093.
38. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54. doi:10.1016/S0092- 8674(01)00507-4. PubMed: 11595184.
39. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B et al. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420. doi:10.1016/j.ccr.2007.04.001. PubMed: 17482131.
40. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW et al. (2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3: 94ra70. PubMed: 21813754.
41. Niu X, Zhang T, Liao L, Zhou L, Lindner DJ et al. (2012) The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31: 776-786. doi:10.1038/onc.2011.266. PubMed: 21725364.
42. Boone DN, Lee AV (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17: 161-173. doi:10.1615/CritRevOncog.v17.i2.30. PubMed: 22471706.
43. Oh Y, Müller HL, Lamson G, Rosenfeld RG (1993) Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268: 14964-14971. PubMed: 7686909.
44. Oh Y, Müller HL, Pham H, Rosenfeld RG (1993) Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268: 26045-26048. PubMed: 7504671.
45. Butt AJ, Firth SM, King MA, Baxter RC (2000) Insulin-like growth factorbinding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275: 39174-39181. doi:10.1074/jbc.M908888199. PubMed: 10998426.
46. H-Zadeh AM, Collard TJ, Malik K, Hicks DJ, Paraskeva C et al. (2006) Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. Int J Oncol 29: 1279-1286. PubMed: 17016662.